Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of SHR-4298 injection, a novel anti-tumor drug [1] Group 1: Product Development - SHR-4298 injection is a first-class therapeutic biological product developed independently by the company [1] - The drug has shown good anti-tumor activity in preclinical animal models and is intended for the treatment of advanced solid tumors [1] - Currently, there are no similar drugs approved for marketing domestically or internationally [1] Group 2: Financial Investment - The cumulative research and development investment for the SHR-4298 injection project has reached approximately 28.79 million yuan [1]